How much funding has Cajal Neuroscience raised?

Cajal Neuroscience has raised $96.0M in total funding, most recently a series a round.

Where is Cajal Neuroscience headquartered?

Cajal Neuroscience is headquartered in Seattle, Washington, United States.

Cajal Neuroscience

Q: Who are Cajal Neuroscience's investors?

Cajal Neuroscience's investors include The Column Group, Lux Capital, Two Sigma Ventures, Evotec, Bristol Myers Squibb, Alexandria Venture Investments.

Home — Cajal Therapeutics

Seattle, United States · $96.0M raised

Headquarters: Seattle, Washington
Business Model: B2B
Website: cajalneuro.com

Total Funding: $96.0M
Last Round: $96.0M Series ANov 2022
Rounds: 1

About

Cajal Neuroscience is a Seattle-based biotechnology company integrating human genetics, functional genomics, and advanced microscopy to discover novel targets and therapeutics for neurodegeneration. Founded in 2021, the company applies computational biology and high-throughput functional validation to understand the mechanistic, spatial, and temporal complexity of neurodegenerative diseases.

Summary

Cajal Neuroscience is a company based in Seattle, United States. It has raised $96.0M in total across 1 round, most recently a $96.0M Series A round in Nov 2022. Investors include The Column Group, Lux Capital and Two Sigma Ventures.